<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-154464</identifier>
<setSpec>0212-1611</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Comparative study on the efficacy and safety of parenteral nutrition formulated with two different fat emulsions: SMOFlipid® compared with Clinoleic®. Preliminary study</dc:title>
<dc:description xml:lang="en">Introduction: The fat composition of parenteral nutrition formulae has been put forward as a possible factor in clinical evolution. Objective: To evaluate the differences in efficacy and safety of two (2) fat emulsions for parenteral nutrition. Material and methods: Prospective clinical study of post-surgery patients under PN for more than seven days in a two-year period. Two types of fat emulsions were administered indistinctively. One is enriched with omega 3 fatty acids (SMOFlipid Fresenius Kabi®), the other one is enriched with omega 9 oleic acid (Clinoleic Baxter®). Epidemiological and analytical variables, infectious complications and mortality were analysed. Results: A total of 154 patients were studied. Their average age was 64.36 ± 13.73 years; 95 were men (61%). Out of the total number, 78 (51%) were given SMOFlipid® and 76 (49%) Clinoleic®. Average stay was 16.91 ± 4.23 days, parenteral nutrition was administered for 9.68 ± 3.25 days, mortality was 11%. 58 (37%) infections were diagnosed. When measured on the first (1st) and seventh (7th) days, there were no significant differences in regard to the lipid, hepatic or nutritional parameters, nor in their evolution (average stay, infectious complications, or mortality) between the two groups of patients. Conclusion: Patients on parenteral nutrition show similar evolutionary characteristic, independently of the fat emulsion administered. Current bibliography would suggest that a benefit could be gained from reducing the administration of omega 9 fatty acids, but no significant differences were found when comparing the two formulae (AU)</dc:description>
<dc:creator>Caballero Requejo, Carmen</dc:creator>
<dc:creator>Palacio Vales, Paula</dc:creator>
<dc:creator>Serrano Navarro, Juana María</dc:creator>
<dc:creator>Martínez-Lozano Aranaga, Fátima</dc:creator>
<dc:creator>Gómez Ramos, María Jesús</dc:creator>
<dc:creator>Sánchez Álvarez, Carmen</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Introducción: la composición lipídica de las fórmulas de nutrición parenteral (NP) se postula como posible factor de evolución clínica. Objetivo: evaluar las diferencias en eficacia y seguridad de dos emulsiones lipídicas en NP. Material y métodos: estudio clínico prospectivo de pacientes posquirúrgicos sometidos a NP durante más de 7 días en un periodo de 2 años. Se administraron de forma indistinta 2 tipos de emulsiones lipídicas: enriquecida con ácidos grasos omega 3 (SMOFlipid Fresenius Kabi®) o con ácido oleico omega 9 (Clinoleic Baxter®). Se analizaron variables epidemiológicas, analíticas, complicaciones infecciosas y mortalidad. Resultados: se estudió un total de 154 pacientes con edad media de 64,36 ± 13,73 años, de los que 95 eran hombres (61%), 78 (51%) recibieron SMOFlipid® y 76 (49%) Clinoleic®. La estancia media fue de 16,91 ± 4,23 días, la duración de la NP 9,68 ± 3,25 días y la mortalidad del 11%. Se diagnosticaron 58 (37%) infecciones. No existieron diferencias significativas en cuanto a los parámetros analíticos lipídicos, hepáticos o nutricionales (medidos al inicio y al 7.º día) ni en su evolución (estancia media, complicaciones infecciosas ni mortalidad) entre los dos grupos de pacientes. Conclusión: los pacientes sometidos a NP presentan similares características evolutivas con independencia de la emulsión lipídica utilizada. La bibliografía actual apunta a un beneficio de la disminución del aporte de ácidos grasos omega 9, pero no se han encontrado diferencias significativas entre las fórmulas comparadas (AU)</dc:description>
<dc:source>Nutr Hosp;33(3): 515-521, mayo-jun. 2016. tab</dc:source>
<dc:identifier>ibc-154464</dc:identifier>
<dc:title xml:lang="es">Estudio comparativo de la eficacia y seguridad de una nutrición parenteral formulada con dos lípidos distintos: SMOFlipid® frente a Clinoleic®. Estudio preliminary</dc:title>
<dc:subject>^d11621^s22045</dc:subject>
<dc:subject>^d30401^s22045</dc:subject>
<dc:subject>^d8230^s22000</dc:subject>
<dc:subject>^d28607</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d5321^s22000</dc:subject>
<dc:subject>^d54124^s22078</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d22780</dc:subject>
<dc:type>article</dc:type>
<dc:date>201606</dc:date>
</metadata>
</record>
</ibecs-document>
